5-(1H-Imidazol-1-yl)-2-methylpyridine

Catalog No.: 
ACTRPI173
CAS No.: 
1376219-87-2
Molecular Formula: 
C9H9N3
Molecular Weight: 
159.19
5-(1H-Imidazol-1-yl)-2-methylpyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$270.00InquiryInquiry
100mg95%$393.00InquiryInquiry
250mg95%$556.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(1H-Imidazol-1-yl)-2-methylpyridine
IUPAC Name5-(1H-imidazol-1-yl)-2-methylpyridine
MDL No.MFCD22056351
Molecular FormulaC9H9N3
Molecular Weight159.19
SMILESCC1=NC=C(N2C=CN=C2)C=C1
InChI KeyWVRGRAUQQFMCMY-UHFFFAOYSA-N
Synonym5-(1H-imidazol-1-yl)-2-methylpyridine;Pyridine, 5-(1H-imidazol-1-yl)-2-methyl-
CAS No.1376219-87-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACTRPI173 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYHFL726 route compound structure diagram
    ACYHFL726695-17-0In Stock
  2. Plus
  3. ACDLYM406 route compound structure diagram
    ACDLYM4065587-42-8In Stock
  4. Then
  5. ACTRPI173 route product structure diagram
    ACTRPI1731376219-87-2
Inquiry

2. ACTRPI173 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDZLF031 route compound structure diagram
    ACDZLF031659742-21-9In Stock
  2. Plus
  3. ACDLYM406 route compound structure diagram
    ACDLYM4065587-42-8In Stock
  4. Then
  5. ACTRPI173 route product structure diagram
    ACTRPI1731376219-87-2
Inquiry

3. ACTRPI173 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTRPI173 route product structure diagram
    ACTRPI1731376219-87-2
Inquiry

Comments (0)